SLC5A2 and chronic kidney disease: Owing to the limited amount of UGE observed with canagliflozin treatment in patients with more severe renal insufficiency 18, SGLT2 inhibitors are not expected to be efficacious for patients with an eGFR <30 ml/min/1.73 m2 (i.e. stages 4 or 5 CKD) or for dialysis patients.